Hutchmed (China) gets NMPA conditional approval for Atled in China
Hutchmed (China) announced NMPA conditional approval for Atled (fantegratinib) in China.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.